USD 2.42 billion
Non-alcoholic Steatohepatitis Biomarkers Market Size, Share, Growth Analysis, By Type(liver fibrosis biomarkers and genetic biomarkers), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35A2593 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|Tables:
34
|Figures:
74
Non-alcoholic Steatohepatitis Biomarkers Market Insights
Non-Alcoholic Steatohepatitis Biomarkers Market size was valued at USD 3.25 billion in 2022 and is poised to grow from USD 4.37billion in 2023 to USD 46.81 billion by 2031, growing at a CAGR of 34.50% in the forecast period (2024-2031).
The Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is experiencing significant growth and is driven by several factors. The market is witnessing increasing prevalence of NASH, which is a chronic liver disease associated with obesity and metabolic disorders.
As the incidence of NASH continues to rise, the demand for accurate and reliable biomarkers for early diagnosis, disease progression monitoring, and therapeutic response evaluation is increasing.
Biomarkers play a crucial role in identifying individuals at risk of developing NASH, differentiating NASH from other liver diseases, and assessing the severity and progression of the disease. Additionally, the market is benefiting from ongoing advancements in biomarker research and development, including the discovery of novel biomarkers and the development of non-invasive diagnostic tools.
Overall, the Global NASH Biomarkers market is poised for growth as it addresses the unmet need for effective diagnostic and monitoring tools for NASH, offering opportunities for market players to introduce innovative biomarker-based solutions.
Market Snapshot - 2024-2031
Global Market Size
Largest Segment
liver fibrosis biomarkers
Fastest Growth
liver fibrosis biomarkers
Growth Rate
34.5% CAGR
Global Non-alcoholic Steatohepatitis Biomarkers Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Non-alcoholic Steatohepatitis Biomarkers Market Segmental Analysis
The global non-alcoholic steatohepatitis biomarkers market is segmented by type, application, and region. Based on type, the market can be segmented into liver fibrosis biomarkers and genetic biomarkers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Analysis by Type
The dominant sub-segment in the type segment of the NASH Biomarkers market is the liver fibrosis biomarkers. Liver fibrosis is a common consequence of NASH and is an important indicator of disease progression. Biomarkers such as enhanced liver fibrosis (ELF) score, FibroTest, and FibroScan are commonly used to assess the degree of liver fibrosis and determine the stage of the disease. These biomarkers help clinicians in evaluating the severity of NASH and making treatment decisions.
The fastest growing sub-segment in the type of the NASH Biomarkers market is the genetic biomarkers. Genetic biomarkers involve the analysis of specific genes or genetic variations associated with NASH. As our understanding of the genetic basis of NASH improves, genetic biomarkers are gaining importance in diagnosing and predicting the risk of developing NASH. Genetic tests, such as genetic profiling and single nucleotide polymorphism (SNP) analysis, are increasingly being used to identify individuals at high risk for NASH and tailor personalized treatment strategies.
Global Non-alcoholic Steatohepatitis Biomarkers Market By Type
To get detailed analysis on other segments, Request For Free Sample Report
Non-alcoholic Steatohepatitis Biomarkers Market Regional Insights
One dominant region in the global non-alcoholic steatohepatitis (NASH) biomarkers market is North America. North America has a well-established healthcare infrastructure, advanced diagnostic technologies, and a high prevalence of NASH, making it a key region for NASH biomarker research and development. The region is home to several major pharmaceutical and biotechnology companies that are actively involved in developing and commercializing NASH biomarkers. Additionally, North America has a strong regulatory framework and reimbursement policies that support the adoption of biomarker-based diagnostics in clinical practice.
One of the fastest growing regions in the global NASH biomarkers market is the Asia-Pacific region. The Asia-Pacific region is witnessing a rising prevalence of NASH due to the increasing prevalence of obesity, sedentary lifestyle, and changing dietary habits. Moreover, there is a growing awareness among healthcare professionals and patients regarding the early detection and management of NASH. As a result, there is an increasing demand for biomarker-based diagnostics in this region. Additionally, countries like China and India are investing in healthcare infrastructure development and research initiatives, which further fuels the growth of the NASH biomarkers market in the Asia-Pacific region.
Global Non-alcoholic Steatohepatitis Biomarkers Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Non-alcoholic Steatohepatitis Biomarkers Market Dynamics
Drivers
Increasing Prevalence Of Nash Worldwide
- One driver of the global NASH biomarkers market is the increasing prevalence of NASH worldwide. NASH is a liver disease characterized by the accumulation of fat in the liver, leading to inflammation and damage. The rising incidence of obesity, sedentary lifestyle, and unhealthy dietary habits are contributing to the growing prevalence of NASH. As a result, there is a need for effective biomarkers that can accurately diagnose NASH, monitor disease progression, and assess treatment response. The demand for NASH biomarkers is driven by the growing awareness of the disease and the need for better diagnostic tools.
Restraints
Lack Of Standardized Biomarkers And Regulatory Challenges
- On the other hand, a significant restraint of the market is the lack of standardized biomarkers and regulatory challenges. The development and validation of biomarkers for NASH diagnosis and monitoring are complex processes. There is a lack of consensus on the selection and use of biomarkers, which hinders their widespread adoption. Additionally, regulatory agencies have stringent requirements for biomarker validation, which can be time-consuming and costly for companies. These challenges pose obstacles to the commercialization and adoption of NASH biomarkers in clinical practice. Further research, standardization, and regulatory guidance are necessary to address these restraints and unlock the full potential of NASH biomarkers in improving patient outcomes.
Request Free Customization of this report to help us to meet your business objectives.
Non-alcoholic Steatohepatitis Biomarkers Market Competitive Landscape
The global market is characterized by a mix of established companies and emerging players. Market participants are focusing on research and development activities to enhance the efficiency and performance of Non-alcoholic Steatohepatitis Biomarkerss. Additionally, strategic collaborations, partnerships, and mergers and acquisitions are prevalent strategies adopted by companies to expand their market presence. The competitive environment is further influenced by factors such as technological advancements, government regulations, and the ability to provide cost-effective and sustainable solutions.
Top Player’s Company Profiles
- Genfit SA - France
- Intercept Pharmaceuticals, Inc. - United States
- Gilead Sciences, Inc. - United States
- Novartis AG - Switzerland
- Pfizer Inc. - United States
- Siemens Healthineers AG - Germany
- Bio-Rad Laboratories, Inc. - United States
- Abbott Laboratories - United States
- Echosens - France
- Prometheus Laboratories Inc. - United States
- NGM Biopharmaceuticals, Inc. - United States
- Metabolon, Inc. - United States
- Perspectum Ltd - United Kingdom
- Precision Medicine Group, Inc. - United States
- Grifols, S.A. - Spain
- Hologic, Inc. - United States
- Quest Diagnostics Incorporated - United States
- F. Hoffmann-La Roche Ltd - Switzerland
- Biopredictive - France
- Medpace Holdings, Inc. - United States
Recent Developments
- In February 2023, Biopredictive Biotech announced the successful development of a novel blood-based biomarker panel for early detection of NASH. The panel shows promising accuracy in identifying patients at risk and differentiating NASH from other liver diseases.
- In April 2023, BioGenomics Inc. unveiled a groundbreaking imaging biomarker for NASH assessment. The non-invasive imaging technique provides detailed visualization and quantification of liver fat, inflammation, and fibrosis, aiding in disease staging and treatment monitoring.
- In June 2023, NASH Diagnostics Ltd. introduced a cutting-edge genetic biomarker test for NASH susceptibility. The test analyzes specific gene variants associated with NASH development and provides personalized risk assessment, allowing clinicians to identify high-risk individuals and implement preventive strategies.
Non-alcoholic Steatohepatitis Biomarkers Key Market Trends
- One key market trend in the market is the increasing focus on non-invasive diagnostic techniques. As NASH is a complex and progressive liver disease, early and accurate diagnosis is crucial for effective management and treatment. Non-invasive biomarkers, such as blood-based tests and imaging techniques, offer advantages over invasive liver biopsies, including lower patient discomfort, reduced costs, and wider accessibility. The development and adoption of non-invasive biomarkers for NASH diagnosis are gaining traction, driven by the need for reliable and convenient diagnostic tools. This trend is expected to enhance patient outcomes, streamline clinical trials, and drive the growth of the global NASH biomarkers market.
Non-alcoholic Steatohepatitis Biomarkers Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
The global non-alcoholic steatohepatitis (NASH) biomarkers market is witnessing significant growth due to the increasing prevalence of non-alcoholic fatty liver disease (NAFLD) and NASH worldwide. NASH biomarkers play a crucial role in diagnosing and monitoring the progression of the disease, as well as evaluating the efficacy of therapeutic interventions. These biomarkers help in assessing liver fibrosis, inflammation, and oxidative stress, providing valuable insights for patient management and treatment decisions. The market is driven by the growing demand for non-invasive diagnostic tools, advancements in biomarker discovery technologies, and the rising awareness about NASH and its associated complications. As the healthcare industry focuses on personalized medicine and targeted therapies, the development and commercialization of reliable and accurate NASH biomarkers hold great promise in improving patient outcomes and optimizing healthcare resources.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 3.25 billion |
| Market size value in 2031 | USD 46.81 billion |
| Growth Rate | 34.50% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Non-alcoholic Steatohepatitis Biomarkers Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Non-alcoholic Steatohepatitis Biomarkers Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Non-alcoholic Steatohepatitis Biomarkers Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Non-alcoholic Steatohepatitis Biomarkers Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Non-alcoholic Steatohepatitis Biomarkers Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Non-alcoholic Steatohepatitis Biomarkers Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
